Coldstream Capital Management Inc. Sells 28,756 Shares of Zoetis Inc. $ZTS

Key Points

• Coldstream Capital Management sharply reduced its Zoetis stake by 83.4% in the fourth quarter, selling 28,756 shares and leaving it with 5,727 shares worth about $721,000.
• Zoetis reported mixed quarterly results, posting EPS of $1.53 versus the $1.60 consensus and revenue of $2.26 billion versus $2.30 billion expected, even though revenue rose 2.9% year over year.
• The company declared a quarterly dividend of $0.53 per share, payable September 1, while analysts currently rate the stock a consensus Hold with an average price target of $133.92.

Coldstream Capital Management Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,727 shares of the company's stock after selling 28,756 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Zoetis were worth $721,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter worth about $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis during the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $32,000. Institutional investors own 92.80% of the company's stock.

Insider Activity

In other news, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company's stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company's stock.

Zoetis Stock Performance

ZTS opened at $79.48 on Thursday. The stock has a market cap of $33.32 billion, a PE ratio of 13.18, a P/E/G ratio of 1.31 and a beta of 0.87. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $172.23. The stock's 50 day simple moving average is $105.95 and its 200-day simple moving average is $117.60.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis's payout ratio is currently 35.16%.

Analyst Ratings Changes

Several brokerages recently weighed in on ZTS. JPMorgan Chase & Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Argus restated a "hold" rating on shares of Zoetis in a research note on Wednesday. Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Wall Street Zen downgraded Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Finally, Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a research note on Friday, February 13th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Hold" and an average price target of $133.92.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.